Kava anxiety depression spectrum study (KADSS): A mixed methods RCT using an aqueous extract of Piper methysticum

Sarris, Jerome, Kavanagh, D. J., Adams, J., Bone, K. and Byrne, G. (2009) Kava anxiety depression spectrum study (KADSS): A mixed methods RCT using an aqueous extract of Piper methysticum. Complementary Therapies in Medicine, 17 3: 176-178. doi:10.1016/j.ctim.2009.01.001


Author Sarris, Jerome
Kavanagh, D. J.
Adams, J.
Bone, K.
Byrne, G.
Title Kava anxiety depression spectrum study (KADSS): A mixed methods RCT using an aqueous extract of Piper methysticum
Formatted title
Kava anxiety depression spectrum study (KADSS): A mixed methods RCT using an aqueous extract of Piper methysticum
Journal name Complementary Therapies in Medicine   Check publisher's open access policy
ISSN 0965-2299
1873-6963
Publication date 2009-06-01
Year available 2009
Sub-type Article (original research)
DOI 10.1016/j.ctim.2009.01.001
Open Access Status
Volume 17
Issue 3
Start page 176
End page 178
Total pages 3
Editor Robbert Van Haselen
Place of publication London, United Kingdom
Publisher Churchill livingstone
Language eng
Subject C1
110499 Complementary and Alternative Medicine not elsewhere classified
920410 Mental Health
Abstract Objectives: To report on the design, significance and potential impacts of the first documented human clinical trial assessing the anxiolytic and thymoleptic efficacy of an aqueous mono-extract of Piper methysticum (kava). The significance of the qualitative element of our clinical. trial is also explored. The Kava Anxiety Depression Spectrum Study (KADSS) is a 3-week placebo-controtled, double-blind, cross-over trial involving 60 adult participants (18-65) with elevated stable anxiety and varying levels of depressive symptoms.
Formatted abstract
Summary:
Objectives: To report on the design, significance and potential impacts of the first documented human clinical trial assessing the anxiolytic and thymoleptic efficacy of an aqueous monoextract of Piper methysticum (kava). The significance of the qualitative element of our clinical
trial is also explored. The Kava Anxiety Depression Spectrum Study (KADSS) is a 3-week placebocontrolled, double-blind, cross-over trial involving 60 adult participants (18—65) with elevated stable anxiety and varying levels of depressive symptoms.

Aims:
The aims of KADSS are: (1) to determine whether an aqueous standardised extract of kava is effective for the treatment of anxiety; (2) to assess the effects of kava on differing levels of depression; and (3) to explore participants’ experience of taking kava via qualitative research.
The study also provides preliminary assessment of the safety of an aqueous extract of kava in humans.

Conclusion:
If results reveal that the aqueous kava preparation exerts significant anxiolytic effects and appears safe, potentially beneficial impacts may occur. Data supporting a safe and effective kava extract may encourage a re-introduction of kava to Europe, UK and Canada. This
may provide a major socioeconomic benefit to Pacific Island nations, and to sufferers of anxiety disorders.
© 2009 Elsevier Ltd. All rights reserved.
Keyword Kava anxiety depression spectrum study (KADSS)
Kava
Aqueous extract
Anxiety
Depression
Mixed methods research
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 4 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 8 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 03 Sep 2009, 18:03:01 EST by Mr Andrew Martlew on behalf of Psychiatry - Royal Brisbane and Women's Hospital